Background <p>The adoptive transfer of T cells engineered to express chimeric antigen receptors (CAR-T) has shown high efficacy and safety in treating various hematologic malignancies. However, many hematologic disorders, such as BCR::ABL1-negative myeloproliferative neoplasms (MPNs), lack effective treatment options. Some of these neoplasms are marked by a recurrent mutation that results in the expression of mutant calreticulin (mCALR), a neoantigen…
Mutant calreticulin enables potent and selective CAR-T cell therapy in preclinical models of myeloproliferative neoplasms
Journal for ImmunoTherapy of Cancer | | Pesini, C., Gil-Bellido, M., S Millan, L., Onate, C., Calvo-Perez, A., Santiago, L., Iglesias, E., Bernal, J. P., Araujo-Voces, M., Paz Artigas, L., Garcia-Martinez, L., Roig, F. J., Movilla Meno, N., Garcia-Aznar, J. M., Menendez-Jandula, B., Olave, M. T., Azaceta Reinares, G., Garrote, M., Alvarez-Larran, A., Galvez, E. M., Sanchez Martinez, D., Arias, M. A., Pardo, J., Ramirez-Labrada, A.
Topics: immunotherapy
Read the full article at Journal for ImmunoTherapy of Cancer